The International Finance Corporation (IFC), part of the World Bank Group, plans to invest US$30 million in PT Etana Biotechnologies Indonesia, a biopharmaceutical company.

This investment aims to support the company’s expansion in local vaccine and biologics production.

The total project cost is estimated at US$60 million, with IFC providing half the funding.

The remaining funds are expected to come from other investors and will be used for developing production facilities, transferring technology, and navigating regulatory processes.

Founded in 2014, Etana focuses on treating non-communicable diseases such as cancer and kidney diseases, along with infectious diseases.

🔗 Source: DailySocial

🧠 Food for thought

1️⃣ Indonesia’s biotech ambitions face an uphill battle despite strategic investments

The IFC’s $30 million investment in Etana reflects a broader push to improve Indonesia’s lagging position in biotech innovation.

Indonesia currently ranks 52nd out of 54 countries in the Global Biotechnology Innovation Scorecard, highlighting the significant gap between the country’s ambitions and its current capabilities in this sector1.

Despite this ranking, Indonesia has shown potential for leadership by becoming the first Southeast Asian nation to utilize mRNA technology for vaccine production, demonstrating capacity for advanced biotech manufacturing1.

The country’s biotech market has already surpassed $2 billion and is projected to grow at an impressive 12.7% CAGR from 2024 to 2032, indicating substantial growth potential that investors like IFC are positioning to capture1.

Etana represents part of a small but growing ecosystem of domestic biotech firms operating primarily in Java, including established players like PT Bio Farma and Kalbe Farma, creating a foundation for future expansion1.

2️⃣ Local production aims to address healthcare affordability challenges

Etana’s expansion comes at a critical time when Indonesia is explicitly focusing on biotech investment to reduce healthcare costs and improve care quality as its national healthcare scheme (JKN) expands to cover more citizens1.

The investment in local biopharmaceutical manufacturing aligns with government initiatives to reduce import dependency for critical medications, particularly as Etana focuses on treatments for non-communicable diseases like cancer that are increasingly prevalent in Indonesia1.